Kristen A Morin
Biographic Data
| ID | 7448666 |
|---|---|
| NAME | Kristen A Morin |
| GIVEN NAMES | Kristen A |
| FAMILY NAME | Morin |
| SIGNATURE | MORIN K A |
| AFFILIATIONS | NOSM University |
| ORCID | 0009-0001-4059-3475 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 3 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2021 |
| LATEST PUBLICATION YEAR | 2022 |
| H-INDEX | 0 |
Association of prescribed oral stimulants on cocaine use among patients enrolled in opioid agonist treatment
The use of oral stimulant prescriptions to treat cocaine use had no clinically significant benefit in a real-world setting. Patients who receive prescriptions for oral stimulants consume more cocaine before and after treatment compared to patients without an oral stimulant prescription. We also observed that cocaine use was reduced with increased time since treatment initiation
Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada
Objective: The objective of this study was to evaluate epidemiological trends of co-use patterns of amphetamine-type stimulants and opioids and the impact of co-use patterns on Opioid Agonist Treatment (OAT) retention in Ontario, Canada. The secondary objective was to assess geographical variation in amphetamine-type stimulant use in Northern Rural, Northern Urban, Southern Rural and Southern Urban Areas of Ontario. Methods: A retrospective cohor…
Evidence of increased Fentanyl use during the Covid-19 pandemic among opioid agonist treatment patients in Ontario, Canada
The use of fentanyl increased by 108% among OAT patients in Ontario during the COVID 19 pandemic. We argue that the persistent increase of fentanyl exposure over time, specifically in the OAT population, suggests that reduced monitoring may decrease OAT's effectiveness and negatively impact patient outcomes
No prominent works on this page.
Negative Impact of Amphetamine-Type Stimulant Use on Opioid Agonist Treatment Retention in Ontario, Canada
Objective: The objective of this study was to evaluate epidemiological trends of co-use patterns of amphetamine-type stimulants and opioids and the impact of co-use patterns on Opioid Agonist Treatment (OAT) retention in Ontario, Canada. The secondary objective was to assess geographical variation in amphetamine-type stimulant use in Northern Rural, Northern Urban, Southern Rural and Southern Urban Areas of Ontario. Methods: A retrospective cohor…
Evidence of increased Fentanyl use during the Covid-19 pandemic among opioid agonist treatment patients in Ontario, Canada
The use of fentanyl increased by 108% among OAT patients in Ontario during the COVID 19 pandemic. We argue that the persistent increase of fentanyl exposure over time, specifically in the OAT population, suggests that reduced monitoring may decrease OAT's effectiveness and negatively impact patient outcomes
Association of prescribed oral stimulants on cocaine use among patients enrolled in opioid agonist treatment
The use of oral stimulant prescriptions to treat cocaine use had no clinically significant benefit in a real-world setting. Patients who receive prescriptions for oral stimulants consume more cocaine before and after treatment compared to patients without an oral stimulant prescription. We also observed that cocaine use was reduced with increased time since treatment initiation
Agonist (3 works) · Anesthesia (3 works) · Internal Medicine (3 works) · Medicine (3 works) · Opioid (3 works) · Opioid Use Disorder Treatment (3 works) · Psychiatry (2 works) · Receptor (2 works) · Amphetamine (1 work) · Attention Deficit Hyperactivity Disorder (1 work)